Calcium and Gut Hormones
The Effect of Calcium Ingestion on Gut Hormone Secretion.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Bath, United Kingdom, BA2 7AY
- Department for Health, University of Bath
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy men and women age between 18-65 yrs.
- Able to consume provided supplement.
- Weight stable for the past 3 month (no change within 3%)
Exclusion Criteria:
- Any previous or current metabolic, cardio-pulmonary or musculoskeletal disease
- Not between the ages of 18-65 years
- A body mass index below 18.5 kg/m2 or above 30 kg/m2 (body mass (kg) divided by your height (m) squared)
- Taking medications that may influence your metabolism
- Plans to change your lifestyle (diet and/or physical activity) during the study period
- Not willing to refrain from alcohol containing drinks or unaccustomed exercise one day before the laboratory sessions.
- Current smoker
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Control
Water with artificial sweetener
|
Water with 80 mg sucralose
|
|
Experimental: Milk mineral supplement
Milk Minerals containing 1000 mg calcium with artificial sweetener and water
|
Water with milk mineral supplement (1000 mg calcium), plus 80 mg sucralose
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Postprandial plasma GLP-1 area under the curve (mmol/L x 120 min).
Time Frame: 120 min
|
Postprandial plasma GLP-1 area under the curve (mmol/L x 120 min).
|
120 min
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Postprandial plasma GIP area under the curve (mmol/L x 120 min)
Time Frame: 120 min
|
Postprandial plasma GIP area under the curve (mmol/L x 120 min)
|
120 min
|
|
Postprandial plasma PYY area under the curve (mmol/L x 120 min)
Time Frame: 120 min
|
Postprandial plasma PYY area under the curve (mmol/L x 120 min)
|
120 min
|
|
Subjective ratings of appetite (au)
Time Frame: 120 min
|
Subjective ratings of appetite (au)
|
120 min
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- REACH EP 16/17_164C
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
NCT06671119RecruitingObesity Prevention | Obesity Recidivism | Obesity and Overweight | Obesity and Obesity-related Medical Conditions
-
NCT05938335Not yet recruiting
-
NCT02645422Enrolling by invitation
-
NCT04780828CompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, Visceral
-
NCT03843424CompletedOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood
-
NCT03203161Not yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric Surgery
-
NCT03219658Completed
-
NCT03899311Completed
-
NCT06734312RecruitingObesity Prevention | Obesity Recidivism | Obesity and Overweight | GLP-1 | Obesity and Obesity-related Medical Conditions | Ablation Techniques
-
NCT04698135CompletedMorbid Obesity | Metabolically Healthy Obesity
Clinical Trials on Control
-
NCT07313956Enrolling by invitationCritical Illness | Respiratory Failure | Mechanical Ventilation
-
NCT02453906Completed
-
NCT00961168Withdrawn
-
NCT06352619Recruiting
-
NCT01422421CompletedCoronary Artery Disease | Hypertension | Type 2 Diabetes | Dyslipidemia
-
NCT03896490CompletedVery Premature Baby
-
NCT03605303TerminatedRefractive Error Correction
-
NCT04084873UnknownChronic Pain | Fibromyalgia
-
NCT05563779CompletedRespiratory Failure